## Nada Boå¾ina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/486173/publications.pdf

Version: 2024-02-01

77 papers 1,523 citations

331670
21
h-index

36 g-index

79 all docs

79 docs citations

79 times ranked 2184 citing authors

#	Article	IF	CITATIONS
1	Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk. Arhiv Za Higijenu Rada I Toksikologiju, 2009, 60, 217-242.	0.7	147
2	A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS ONE, 2016, 11, e0162866.	2.5	96
3	The role of CYP2D6 and ABCB1 pharmacogenetics in drug-na $\tilde{\mathbb{A}}$ -ve patients with first-episode schizophrenia treated with risperidone. European Journal of Clinical Pharmacology, 2010, 66, 1109-1117.	1.9	80
4	Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. Journal of Psychiatric Research, 2008, 42, 89-97.	3.1	70
5	Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croatian Medical Journal, 2003, 44, 425-8.	0.7	70
6	The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the bloodâ€"brain barrier in patients with generalized epilepsy. Seizure: the Journal of the British Epilepsy Association, 2008, 17, 524-530.	2.0	69
7	MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1439-1444.	4.8	62
8	The influence of 5-HT2C and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Research, 2008, 160, 308-315.	3.3	55
9	Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Pharmacogenomics, 2015, 16, 137-148.	1.3	47
10	Association Between Lamotrigine Concentrations and ABCB1 Polymorphisms in Patients With Epilepsy. Therapeutic Drug Monitoring, 2012, 34, 518-525.	2.0	40
11	How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity / Kako polimorfizmi gena citokroma P450 utjeÄu na metabolizam i toksiÄnost ibuprofena i diklofenaka. Arhiv Za Higijenu Rada I Toksikologiju, 2016, 67, 1-8.	0.7	40
12	Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. Journal of Psychopharmacology, 2007, 21, 728-734.	4.0	37
13	Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World Journal of Biological Psychiatry, 2008, 9, 190-197.	2.6	36
14	The Association Study of Polymorphisms in DAT, DRD2, and COMT Genes and Acute Extrapyramidal Adverse Effects in Male Schizophrenic Patients Treated With Haloperidol. Journal of Clinical Psychopharmacology, 2013, 33, 593-599.	1.4	35
15	Adverse drug reactions caused by drug-drug interactions reported to Croatian Agency for Medicinal Products and Medical Devices: a retrospective observational study. Croatian Medical Journal, 2011, 52, 604-614.	0.7	34
16	Treatment-resistant schizophrenia and DAT and SERT polymorphisms. Gene, 2014, 543, 125-132.	2.2	33
17	Monoamine Oxidase A Gene Methylation and Its Role in Posttraumatic Stress Disorder: First Evidence from the South Eastern Europe (SEE)-PTSD Study. International Journal of Neuropsychopharmacology, 2018, 21, 423-432.	2.1	33
18	<i>ABCG2</i> gene polymorphisms as risk factors for atorvastatin adverse reactions: a case–control study. Pharmacogenomics, 2015, 16, 803-815.	1.3	32

#	Article	IF	CITATIONS
19	CYP2C9andABCG2polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case–control study. Pharmacogenomics, 2013, 14, 1419-1431.	1.3	29
20	Genetic polymorphisms of cytochrome P450 enzymes: <i>CYP2C9</i> , <i>CYP2C19</i> , <i>CYP2D6</i> , <i>CYP3A4</i> , and <i>CYP3A5</i> in the Croatian population. Drug Metabolism and Personalized Therapy, 2017, 32, 11-21.	0.6	27
21	Adiponectin Level and Gene Variability Are Obesity and Metabolic Syndrome Markers in a Young Population. Archives of Medical Research, 2012, 43, 145-153.	3.3	25
22	Interaction between <i>ABCG2 421C&gt;A</i> polymorphism and valproate in their effects on steadyâ€state disposition of lamotrigine in adults with epilepsy. British Journal of Clinical Pharmacology, 2018, 84, 2106-2119.	2.4	24
23	Rosuvastatinâ€Induced Rhabdomyolysis – Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 509-518.	2.5	22
24	Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug–drug interaction. International Journal of Clinical Pharmacy, 2012, 34, 825-827.	2.1	20
25	Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients With Atrial Fibrillation: A Randomized Parallel Group Trial. Therapeutic Drug Monitoring, 2018, 40, 362-368.	2.0	20
26	GENETIC SUSCEPTIBILITY TO POSTTRAUMATIC STRESS DISORDER: ANALYSES OF THE OXYTOCIN RECEPTOR, RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR A AND CANNABINOID RECEPTOR 1 GENES. Psychiatria Danubina, 2019, 31, 219-226.	0.4	19
27	Clinical Application of Genotype-guided Dosing of Warfarin in Patients with Acute Stroke. Archives of Medical Research, 2015, 46, 265-273.	3.3	18
28	Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. Nordic Journal of Psychiatry, 2017, 71, 513-520.	1.3	18
29	Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy. Collegium Antropologicum, 2013, 37, 41-5.	0.2	18
30	Serotonin transporter polymorphism in Croatian patients with major depressive disorder. Psychiatria Danubina, 2006, 18, 83-9.	0.4	14
31	Platelet serotonin in primary Sjögren's syndrome: Level and relation with disease activity. Journal of Neuroimmunology, 2012, 251, 87-89.	2.3	11
32	Effect of Cyclosporine on Steady-State Pharmacokinetics of MPA in Renal Transplant Recipients Is Not Affected by the MPA Formulation. Therapeutic Drug Monitoring, 2014, 36, 456-464.	2.0	11
33	Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions. European Journal of Clinical Pharmacology, 2017, 73, 1129-1140.	1.9	11
34	Characterization of ADME genes variation in Roma and 20 populations worldwide. PLoS ONE, 2018, 13, e0207671.	2.5	11
35	THE ROLE OF TAQI DRD2 (RS1800497) AND DRD4 VNTR POLYMORPHISMS IN POSTTRAUMATIC STRESS DISORDER (PTSD). Psychiatria Danubina, 2019, 31, 263-268.	0.4	10
36	Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy. Psychiatria Danubina, 2010, 22, 335-7.	0.4	10

#	Article	IF	CITATIONS
37	Clinical Significance of a CYP2D6 Poor Metabolizer -A Patient With Schizophrenia on Risperidone Treatment. Therapeutic Drug Monitoring, 2008, 30, 748-751.	2.0	9
38	<i>CYP2D6 *6/*6</i> genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms. Pharmacogenomics, 2016, 17, 1385-1389.	1.3	9
39	Association of CNR1 genotypes with changes in neurocognitive performance after eighteen-month treatment in patients with first-episode psychosis. European Psychiatry, 2019, 61, 88-96.	0.2	9
40	ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110042.	4.8	9
41	Effect of antiepileptic drug comedication on lamotrigine concentrations. Croatian Medical Journal, 2018, 59, 13-19.	0.7	8
42	<i>DPYD</i> polymorphisms <i>c.496A&gt;G</i> , <i>c.2194G&gt;A</i> and <i>c.85T&gt;C</i> and risk of severe adverse drug reactions in patients treated with fluoropyrimidineâ€based protocols. British Journal of Clinical Pharmacology, 2022, 88, 2190-2202.	2.4	8
43	Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population. Arhiv Za Higijenu Rada I Toksikologiju, 2017, 68, 180-184.	0.7	7
44	THE ASSOCIATION OF CATECHOL-O-METHYL-TRANSFERASE AND INTERLEUKIN 6 GENE POLYMORPHISMS WITH POSTTRAUMATIC STRESS DISORDER. Psychiatria Danubina, 2019, 31, 241-248.	0.4	7
45	Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case–control study. European Journal of Clinical Pharmacology, 2021, , 1.	1.9	7
46	Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drug–drug interaction. Cancer Chemotherapy and Pharmacology, 2015, 76, 1317-1319.	2.3	6
47	CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419. International Journal of Cardiology, 2015, 186, 282-285.	1.7	6
48	Dapsoneâ€induced agranulocytosis—possible involvement of lowâ€activity <i>N</i> â€acetyltransferase 2. Fundamental and Clinical Pharmacology, 2017, 31, 580-586.	1.9	6
49	Pharmacogenetics and the treatment of epilepsy: what do we know?. Pharmacogenomics, 2019, 20, 1093-1101.	1.3	6
50	Lack of association of SCN2A rs17183814 polymorphism with the efficacy of lamotrigine monotherapy in patients with focal epilepsy from Herzegovina area, Bosnia and Herzegovina. Epilepsy Research, 2019, 158, 106221.	1.6	6
51	Pharmacogenetics and statin-related myopathy: what do we know?. Pharmacogenomics, 2020, 21, 821-825.	1.3	6
52	VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 905-913.	0.6	6
53	Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 â€" Implications for warfarin management and outcome in Croatian patients with acute stroke. Journal of the Neurological Sciences, 2014, 343, 30-35.	0.6	5
54	ASSOCIATION ANALYSIS OF MAOA AND SLC6A4 GENE VARIATION IN SOUTH EAST EUROPEAN WAR RELATED POSTTRAUMATIC STRESS DISORDER. Psychiatria Danubina, 2019, 31, 211-218.	0.4	5

#	Article	IF	CITATIONS
55	ROLE OF THE ALLELIC VARIATION IN THE 5-HYDROXYTRYPTAMINE RECEPTOR 1A (HTR1A) AND THE TRYPTOPHAN HYDROXYLASE 2 (TPH2) GENES IN THE DEVELOPMENT OF PTSD. Psychiatria Danubina, 2019, 31, 256-262.	0.4	5
56	Association of polymorphic variants in serotonin re-uptake transporter gene with Crohn's disease: a retrospective case-control study. Croatian Medical Journal, 2018, 59, 232-243.	0.7	4
57	The lack of influence of IVS5-91 G>A polymorphism of the SCN1A gene on efficacy of lamotrigine in patients with focal epilepsy. Neurological Research, 2019, 41, 930-935.	1.3	4
58	Association of HSPA1B genotypes with psychopathology and neurocognition in patients with the first episode of psychosis: a longitudinal 18-month follow-up study. Pharmacogenomics Journal, 2020, 20, 638-646.	2.0	4
59	A CANDIDATE GENE ASSOCIATION STUDY OF FKBP5 AND CRHR1 POLYMORPHISMS IN RELATION TO WAR-RELATED POSTTRAUMATIC STRESS DISORDER. Psychiatria Danubina, 2019, 31, 269-275.	0.4	4
60	Use of pharmacogenomics in elderly patients treated for cardiovascular diseases. Croatian Medical Journal, 2020, 61, 147-158.	0.7	4
61	Therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis: a case report. European Journal of Clinical Pharmacology, 2009, 65, 1265-1266.	1.9	3
62	Impact of Continuous P2Y12 Inhibition Tailoring in Acute Coronary Syndrome and Genetically Impaired Clopidogrel Absorption. Journal of Cardiovascular Pharmacology, 2020, 75, 174-179.	1.9	3
63	Severe hyperglycaemia following pazopanib treatment: The role of drugâ€drugâ€gene interactions in a patient with metastatic renal cell carcinoma—A case report. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 628-631.	1.5	3
64	Implementation of pharmacogenomics in product information. Pharmacogenomics, 2020, 21, 443-448.	1.3	3
65	ASSOCIATIONS BETWEEN POLYMORPHISMS IN THE SOLUTE CARRIER FAMILY 6 MEMBER 3 AND THE MYELIN BASIC PROTEIN GENE AND POSTTRAUMATIC STRESS DISORDER. Psychiatria Danubina, 2019, 31, 235-240.	0.4	3
66	Association of polygenic risk scores, traumatic life events and coping strategies with war-related PTSD diagnosis and symptom severity in the South Eastern Europe (SEE)-PTSD cohort. Journal of Neural Transmission, $2021$ , , $1$ .	2.8	3
67	Pharmacogenetics in modern psychiatry. Psychiatria Danubina, 2007, 19, 231-3.	0.4	3
68	Olanzapine Long-Acting Injections After Neuroleptic Malignant Syndrome. Journal of Clinical Psychopharmacology, 2016, 36, 733-735.	1.4	2
69	Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review. Arhiv Za Higijenu Rada I Toksikologiju, 2021, 72, 114-128.	0.7	2
70	REMISSION IS NOT ASSOCIATED WITH DRD2 RS1800497 AND DAT1 RS28363170 GENETIC VARIANTS IN MALE SCHIZOPHRENIC PATIENTS AFTER 6-MONTHS MONOTHERAPY WITH OLANZAPINE. Psychiatria Danubina, 2020, 32, 84-91.	0.4	2
71	Pharamacogenetics and antidepressant treatment in integrative psychiatry perspective. Psychiatria Danubina, 2008, 20, 399-401.	0.4	2
72	Rapid clearance of tacrolimus blood concentration triggered by variant pharmacogenes. Journal of Clinical Pharmacy and Therapeutics, 2022, , .	1.5	2

#	Article	IF	CITATIONS
73	Is there any association of apolipoprotein E gene polymorphisms with metabolic syndrome in a young population of Croatian origin?. Annals of Human Biology, 2017, 44, 287-294.	1.0	1
74	The lack of association between COMT rs4680 polymorphism and symptomatic remission to olanzapine monotherapy in male schizophrenic patients: A longitudinal study. Psychiatry Research, 2019, 279, 389-390.	3.3	1
75	Association of methylenetetrahydrofolate reductase C677T CT gene polymorphism with a non-dipping blood pressure pattern in morbidly obese patients. Cardiologia Croatica, 2021, 16, 38-39.	0.0	O
76	Genotype-guided warfarin dosing. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-14-20.	0.0	0
77	Pharmacogenetics and interactions of antidepressants in the treatment of co-morbid illness. Psychiatria Danubina, 2009, 21, 399-400.	0.4	0